This patented technology represents a paradigm shift in biosensor design by adapting industrial electrochemical technology for biomedical applications. Current point-of-care and laboratory diagnostic methods rely on discrete sampling, which fails to capture dynamic physiological changes and may miss clinically significant transient events. The Problem Existing electrochemical biosensors suffer from four critical limitations: • Poor selectivity: Conventional sensors exhibit significant interference from electroactive species in biofluids, including ascorbic acid, uric acid, and acetaminophen, leading to false readings. • Short operational lifetime: Enzyme-based sensors typically decay with half-lives of 3-7 days at physiological temperature due to denaturation and proteolytic degradation. • Biofouling: Protein adsorption and cellular adhesion on electrode surfaces cause signal drift and reduced sensitivity within hours to days of exposure to complex biofluids. • Frequent calibration requirements: Most commercial sensors require calibration 2-4 times daily due to baseline drift, reducing user compliance and accuracy. Our Solution This invention overcomes these limitations through an integrated approach combining advanced electrode engineering, innovative surface functionalization, intelligent signal processing, and optimized microfluidic design. Key Technical Advantages: • Enhanced Selectivity: Achieves interference rejection ratios exceeding 20:1 through a multi-layer selective barrier comprising Nafion cation-exchange polymer and polyurethane size-exclusion membrane, effectively blocking anionic interferents while excluding larger molecules based on size. • Extended Stability: Novel crosslinking protocols using glutaraldehyde and cyanuric chloride achieve enzyme immobilization with retention of over 80% initial activity after 30 days at 37°C, representing a 4-5x improvement over conventional methods. • Anti-Fouling Properties: Zwitterionic polymer brushes grafted to the outer membrane reduce protein adsorption by over 95% compared to unmodified surfaces, maintaining sensor performance in undiluted serum for more than 14 days. • Intelligent Calibration: Adaptive algorithms incorporating machine learning-based drift prediction reduce calibration frequency to once per 14 days while maintaining plus-minus 5% accuracy. Core Innovation The invention leverages electrode architectures originally developed for industrial electrochemical processes, specifically 316L stainless steel anodes and nickel mesh cathodes, adapted for biocompatibility and surface functionalization. This technology transfer from industrial to biomedical applications combines the durability and cost-effectiveness of industrial electrodes with advanced biorecognition capabilities. Performance Metrics • Glucose detection: Sensitivity of 21.5 nA/mM, linear range 0.5-25 mM, limit of detection 12 μM, response time 45 seconds, operational stability exceeding 30 days at 37°C. • IL-6 protein detection: Dynamic range 1-10,000 pg/mL, limit of detection 0.5 pg/mL, selectivity over 50:1 versus related cytokines, regeneration capability for over 20 cycles with greater than 95% signal recovery. • Multi-analyte capability: Simultaneous monitoring of glucose, lactate, inflammatory markers, and cancer biomarkers in a single platform. Target Applications • Diabetes Care: Continuous glucose monitoring for Type 1 and Type 2 diabetes management. • Critical Care: Real-time lactate monitoring in ICU settings for early sepsis detection. • Oncology: PSA and CA-125 surveillance for prostate and ovarian cancer monitoring. • Bioprocessing: Cell culture metabolite monitoring for biopharmaceutical production quality control. Intellectual Property Status • Patent pending with 7 claims covering method, system, and kit configurations. • IPC Classification: G01N 27/327; A61B 5/145; G01N 33/543; C12Q 1/00. • Inventor: Artem G. Teplov | ORCID: 0009-0000-0049-5232. Commercial Opportunity The global biosensor market is projected to reach $44.8 billion by 2028, driven by demand for continuous glucose monitoring, critical care diagnostics, and personalized medicine. Our platform addresses critical pain points for medical device manufacturers and healthcare providers: extended sensor lifetime, reduced calibration burden, multi-analyte capability, and significantly lower cost per test ($2-5 versus $15-25 for laboratory alternatives). Licensing Framework • Non-exclusive evaluation license available for full technical documentation, working examples, and manufacturing specifications. • Commercial licensing negotiable based on application domain, territory, and production volume. • Open to joint R&D partnerships, pilot deployment collaborations, and equity investment in scale-up ventures. Impact Alignment This technology directly supports UN Sustainable Development Goals 3 (Good Health and Well-being) and 9 (Industry, Innovation and Infrastructure) by enabling accessible, accurate, and continuous health monitoring for chronic disease management and early diagnosis. For licensing inquiries, technical collaboration, or investment discussions: Email: Teplov.a.g@gmail.com